Based on these findings, both larotrectinib and entrectinib have secured FDA and European Medicines Agency (EMA) approval for solid tumor patients with TRK gene fusions, showcasing high anti-tumor efficacy across various tumor subtypes and patient age groups [167]. The gene discussed is NTRK1; the disease is neoplasm.